X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (5) 5
index medicus (4) 4
oncology (3) 3
[ sdv.can ] life sciences [q-bio]/cancer (2) 2
bevacizumab (2) 2
cancer (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
carcinoma, non-small-cell lung - genetics (2) 2
care and treatment (2) 2
cell lung-cancer (2) 2
crizotinib (2) 2
egfr (2) 2
female (2) 2
immunology (2) 2
immunotherapy (2) 2
life sciences (2) 2
lung cancer (2) 2
lung neoplasms - drug therapy (2) 2
lung neoplasms - genetics (2) 2
male (2) 2
mutation (2) 2
neoplasm metastasis (2) 2
nsclc (2) 2
protein kinase inhibitors - therapeutic use (2) 2
quality of life (2) 2
respiratory system (2) 2
ros1 (2) 2
abundance (1) 1
acquired resistance (1) 1
acute respiratory-failure (1) 1
adult (1) 1
alk (1) 1
alphabeta integrin (1) 1
angiogenesis inhibitor (1) 1
angiogenesis inhibitors - therapeutic use (1) 1
animals (1) 1
anti-bacterial agents - therapeutic use (1) 1
antibiotics (1) 1
antibodies, monoclonal - therapeutic use (1) 1
antibodies, monoclonal, humanized - therapeutic use (1) 1
anticancer properties (1) 1
antineoplastic agents - therapeutic use (1) 1
antineoplastic agents, hormonal - therapeutic use (1) 1
antineoplastic combined chemotherapy protocols (1) 1
antitumor activity (1) 1
antitumor immunity (1) 1
apoptosis (1) 1
asbestos (1) 1
bacteria (1) 1
brain metastases (1) 1
cancer bronchique (1) 1
cancer immunotherapy (1) 1
cancer therapies (1) 1
cancer-patients (1) 1
cancérologie (1) 1
carcinoma, non-small-cell lung - complications (1) 1
carcinoma, non-small-cell lung - diagnosis (1) 1
carcinoma, non-small-cell lung - mortality (1) 1
ccr9 protein (1) 1
cd103 integrin (1) 1
cd4 antigen (1) 1
cd4 antigens - immunology (1) 1
cd8 tissue resident memory t (t (1) 1
cd8 tissue resident memory t cells (1) 1
cell cycle checkpoints - drug effects (1) 1
cell division (1) 1
cell receptors (1) 1
cells (1) 1
cetuximab (1) 1
chemotherapy (1) 1
colony-stimulating factor (1) 1
crizotinib - therapeutic use (1) 1
cxcr3 protein (1) 1
cyclophosphamide (1) 1
cytotoxic t lymphocytes (1) 1
dic (1) 1
dietary supplements (1) 1
disease progression (1) 1
disease-free survival (1) 1
disseminated intravascular coagulation (1) 1
docetaxel (1) 1
dose weekly erlotinib (1) 1
drug resistance, neoplasm - genetics (1) 1
dyspnea (1) 1
e-cadherin (1) 1
endothelial growth-factor (1) 1
epithelial tumors (1) 1
estradiol - analogs & derivatives (1) 1
estradiol - therapeutic use (1) 1
fecal microbiota transplantation (1) 1
feces (1) 1
feces - microbiology (1) 1
flora (1) 1
fluorescent in situ hybridization (1) 1
forthcoming 8th edition (1) 1
france - epidemiology (1) 1
fusion (1) 1
gastrointestinal microbiome - genetics (1) 1
gastrointestinal microbiome - immunology (1) 1
gene rearrangement (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science, ISSN 0036-8075, 01/2018, Volume 359, Issue 6371, pp. 91 - 97
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical responses in a sizable minority of cancer patients. We found that... 
CELL LUNG-CANCER | MELANOMA | MICROENVIRONMENT | INTESTINAL MICROBIOTA | CYCLOPHOSPHAMIDE | PD-1 BLOCKADE | MULTIDISCIPLINARY SCIENCES | GENES | RESISTANCE | ANTITUMOR IMMUNITY | NIVOLUMAB | CD4 Antigens - immunology | Immunotherapy - methods | Humans | Antibodies, Monoclonal - therapeutic use | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Gastrointestinal Microbiome - genetics | Fecal Microbiota Transplantation | Anti-Bacterial Agents - therapeutic use | Feces - microbiology | Metagenome - genetics | Neoplasms - therapy | Animals | Receptors, CCR - immunology | Interleukin-12 - immunology | Receptors, CXCR3 - immunology | T-Lymphocytes - immunology | Mice | Gastrointestinal Microbiome - immunology | Verrucomicrobia - genetics | Verrucomicrobia - immunology | Care and treatment | Cell receptors | Microbiota (Symbiotic organisms) | Immunotherapy | Epithelial tumors | Physiological aspects | Health aspects | Methods | Apoptosis | PD-1 protein | Interleukin | Microbiomes | Transplantation | Lymphocytes T | Anticancer properties | Microbiota | Lymphocytes | Bacteria | Feces | Supplementation | Gnotobiotics | Kidneys | Melanoma | Dietary supplements | Interleukin 12 | Abundance | CXCR3 protein | Patients | CD4 antigen | Immune checkpoint | Antibiotics | Lungs | Flora | PD-L1 protein | Relative abundance | Antitumor activity | CCR9 protein | Tumors | Kidney transplantation | Cancer | Life Sciences
Journal Article
Future Oncology, ISSN 1479-6694, 12/2017, Volume 13, Issue 28, pp. 2537 - 2546
Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for themajority of... 
bevacizumab | malignant pleural mesothelioma | angiogenesis inhibitor | FORTHCOMING 8TH EDITION | PROGNOSTIC-FACTORS | TNM CLASSIFICATION | OPEN-LABEL | PHASE-II TRIAL | CANCER-PATIENTS | ONCOLOGY | STAGING PROJECT PROPOSALS | IASLC MESOTHELIOMA | PLUS BEVACIZUMAB | ENDOTHELIAL GROWTH-FACTOR
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, p. S700
Journal Article
Bulletin du Cancer, ISSN 0007-4551, 06/2015, Volume 102, Issue 6, pp. S27 - S33
EGFR, ALK, ROS1 Tyrosine Kinase Inhibitors (TKis) have changed natural history of 12 to 15% of patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and... 
ALK | Acquired resistance | Primary resistance | ROS1 | EGFR | Tyrosine kinase inhibitors
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 2019, Volume 14, Issue 8, pp. 1400 - 1407
Introduction: Leptomeningeal metastases (LMs) are associated with dismal prognosis in NSCLC. Optimal management remains unknown in patients with EGFR-mutated... 
NSCLC | Tyrosine kinase inhibitor | Leptomeningeal metastases | EGFR | CELL LUNG-CANCER | ONCOLOGY | RESPIRATORY SYSTEM | BRAIN METASTASES | DOSE WEEKLY ERLOTINIB
Journal Article
Future oncology (London, England), 12/2017, Volume 13, Issue 28, p. 2537
Malignant pleural mesothelioma (MPM) is an aggressive cancer with poor prognosis. Systemic chemotherapy is the primary treatment modality for the majority of... 
Journal Article
La Revue du praticien, 01/2017, Volume 67, Issue 1, p. 47
Therapeutic advances in lung cancer. The molecular dissection of lung cancers led to the development of new oral targeted therapies, mainly kinase inhibitors,... 
Journal Article
La Revue du praticien, 02/2016, Volume 66, Issue 2, p. 191
Malignant pleural mesothelioma: rare and aggressive but with new therapeutic perspectives. CMalignant pleural mesothelioma (MPM) is a rare tumour secondary to... 
Pleural Neoplasms - epidemiology | France - epidemiology | Humans | Antineoplastic Combined Chemotherapy Protocols | Mesothelioma - epidemiology | Quality of Life | Male | Mesothelioma - drug therapy | Pleural Neoplasms - drug therapy
Journal Article
Current Pulmonology Reports, ISSN 2199-2428, 3/2016, Volume 5, Issue 1, pp. 57 - 62
ROS1 is a membrane tyrosine kinase receptor of which encoding gene has recently been found rearranged in non-small cell lung cancer (NSCLC), leading to... 
Crizotinib | ROS-1 | Pneumology/Respiratory System | Medicine & Public Health | Oncogenic drive | Non-small cell lung cancer (NSCLC) | Internal Medicine | Thoracic Surgery | Tyrosine-kinase inhibitors | Fluorescent in situ hybridization (FISH)
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.